JPS62688Y2 - - Google Patents
Info
- Publication number
- JPS62688Y2 JPS62688Y2 JP1981174597U JP17459781U JPS62688Y2 JP S62688 Y2 JPS62688 Y2 JP S62688Y2 JP 1981174597 U JP1981174597 U JP 1981174597U JP 17459781 U JP17459781 U JP 17459781U JP S62688 Y2 JPS62688 Y2 JP S62688Y2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- space
- flow
- separator
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004369 blood Anatomy 0.000 claims description 46
- 239000008280 blood Substances 0.000 claims description 46
- 230000017531 blood circulation Effects 0.000 claims description 21
- 239000012503 blood component Substances 0.000 claims description 18
- 239000000306 component Substances 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 238000004062 sedimentation Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000012388 gravitational sedimentation Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【考案の詳細な説明】
本考案は、血液を重力の沈降作用によつて成分
分離するための改良された血液成分分離器に関す
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an improved blood component separator for separating blood components by gravitational sedimentation.
血液は血漿成分と赤血球、白血球、血小板等の
血球成分とからなつている。近年輸血は採血され
た血液をそのまま輸血するのでなく、これらの成
分別に分離し、夫々の患者が必要とする特定の成
分だけを夫々輸血することが多くなつている。血
液を静置すれば、血球成分は次第に沈殿して血漿
が分離されるが、その速度は遅い。そのため重力
による沈降によらず、遠心分離機を用いる分離法
が従来広く採用されてきた。併し、この方法は高
価な遠心分離機と、その回転動力、更に安全装置
等を必要とする。 Blood consists of plasma components and blood cell components such as red blood cells, white blood cells, and platelets. In recent years, in blood transfusions, instead of directly transfusing collected blood, it has become increasingly common to separate the blood into its components and transfuse only the specific components needed by each patient. If the blood is allowed to stand still, blood cell components will gradually precipitate and plasma will be separated, but this process is slow. For this reason, separation methods using centrifuges have been widely adopted in the past, without relying on sedimentation due to gravity. However, this method requires an expensive centrifugal separator, its rotational power, and safety equipment.
本考案者らは、このような人工的遠心力を用い
ずに重力の沈降作用により、血液の成分分離を極
めて効率的に行なう方法および装置を提供すべく
鋭意検討した結果、血液を薄い層状に連続的に流
すことにより、該血液流を分離された成分層から
なる多層流に移行せしめ、所望の層成分を取得で
きることを見いだし、この原理に係わる血液成分
分離方法および装置を発明し、すでに出願を行な
つている（特願昭56−16190号）。 The inventors of the present invention have conducted extensive research to provide a method and device that can extremely efficiently separate blood components using the sedimentation effect of gravity without using such artificial centrifugal force. They discovered that by continuously flowing the blood flow, the blood flow can be transformed into a multilayer flow consisting of separated component layers, and the desired layer components can be obtained, and they have invented a blood component separation method and device based on this principle, and have already filed a patent application. (Special Application No. 16190, 1983).
このようなことが可能である理由は次のように
考えられる。血液は粘稠な液体であるが、この粘
度を実質的に決定している要因は血液中に含まれ
る赤血球の体積比、すなわちヘマトクリツト値で
ある。正常な人血のヘマトクリツト値は30〜45％
であるが、その粘度は水の粘度の３〜４倍に相当
する。ヘマトクリツト値が60〜70％に達すると、
血液の粘度は水の粘度の６〜９倍に達する。一方
血液中の血漿成分の粘度は、これに含まれる蛋白
質の量と種類にもよるが、水の粘度の1.5〜2.0倍
に過ぎない。本考案者らの観察によると、このよ
うな血液が水平に流れている状態下で血沈その他
の原因によつて、たとえわずかでもひとたび上澄
層と沈殿層とに分離すると、沈殿層は粘度が上昇
してゆき、流そうとする外力に対し流され難いも
のとなつてゆき、逆に上澄層は、ひとたび分離が
始まると、外力によつて流され易いものとなつて
ゆく。一方、血液の粘度は、流れの線速度によつ
ても影響される。すなわち、流れの線速度が小と
なるに従つて血液の粘度は急激に大となつてゆ
く。これは特に、赤血球の相互間の粘着力に基く
凝集力の結果であると考えられる。事実赤血球
は、顕微鏡で観察すると凝集塊を形成し易いもの
であることが確認される。この凝集塊は、いわゆ
る連銭状を呈しているものであることが多い。こ
の現象は沈殿層を流れにくくする一因と考えられ
る。また沈殿層は血沈、すなわち上からの重力に
よる圧密の効果と、流れすなわち横からの外力に
よる圧密の効果とによつて凝集塊を形成し、極め
て効果的に濃縮されてゆくと同時に、凝集塊形成
によつて赤血球の沈降がさらに加速される。流動
下における血液のかかる諸現象が、該発明の血液
分離に有効に働いているものと推定される。すな
わち、何らの可動部分を有しない該発明の容器中
に、単に血液を流すのみによつて効率よく血液の
分離ができる原因と考えられる。 The reason why this is possible is considered to be as follows. Blood is a viscous liquid, and the factor that substantially determines this viscosity is the volume ratio of red blood cells contained in the blood, that is, the hematocrit value. Normal human blood hematocrit value is 30-45%
However, its viscosity is equivalent to 3 to 4 times the viscosity of water. When the hematocrit value reaches 60-70%,
The viscosity of blood reaches 6 to 9 times that of water. On the other hand, the viscosity of plasma components in blood is only 1.5 to 2.0 times the viscosity of water, depending on the amount and type of proteins contained therein. According to the inventors' observations, once blood is separated into a supernatant layer and a precipitate layer, even slightly, due to blood sedimentation or other causes while blood is flowing horizontally, the viscosity of the precipitate layer decreases. As it rises, it becomes difficult to be washed away by external forces that try to drain it, and conversely, once the supernatant layer begins to separate, it becomes easy to be washed away by external forces. On the other hand, blood viscosity is also influenced by the linear velocity of flow. That is, as the linear velocity of the flow decreases, the viscosity of blood increases rapidly. This is particularly thought to be the result of cohesive forces based on the adhesion of red blood cells to each other. In fact, when red blood cells are observed under a microscope, it is confirmed that they tend to form aggregates. This agglomerate often has a so-called roule-like shape. This phenomenon is considered to be one of the reasons why the sediment layer becomes difficult to flow. In addition, the sediment layer forms aggregates due to blood sedimentation, that is, the effect of consolidation due to gravity from above, and the effect of consolidation due to flow, or external force from the side, and is extremely effectively concentrated. Formation further accelerates red blood cell sedimentation. It is presumed that these various phenomena of blood under flowing conditions work effectively in the blood separation of the present invention. In other words, this is considered to be the reason why blood can be efficiently separated simply by flowing blood into the container of the present invention, which does not have any moving parts.
該分離器を用いて血液の成分分離を行なう際に
は、血液の流れをできるだけ乱さないことと、該
分離器内部にできるだけ均一に血液を分布させる
ことが、高い効率で血液成分を分離する上で重要
であり、かかる要求を満たしうる構造をもつた血
液成分分離器の提供が望まれていた。 When separating blood components using the separator, it is important to avoid disturbing the blood flow as much as possible and to distribute the blood as uniformly as possible inside the separator in order to separate blood components with high efficiency. Therefore, it has been desired to provide a blood component separator having a structure that can meet such requirements.
本考案は、血液中の赤血球の凝集を加速するこ
とにより、血液成分分離を行うための分離器であ
つて、血液の導入口に連通し、血液の流れと直角
方向に対して、なだらかに拡大した空間部と、該
空間部に連通した、その垂直方向の厚さが0.2〜
20mmである少なくとも一つの血液流路と、該流路
に連通し、血液の流れと直角方向に対して、なだ
らかに縮少した空間と、該空間部と連通し、血液
の流れと垂直方向に上下離れて設置された少なく
とも２個の血液成分の導出口とからなる血液成分
分離器である。 This device is a separator for separating blood components by accelerating the aggregation of red blood cells in blood. The vertical thickness of the space communicating with the space is 0.2~
at least one blood flow channel having a diameter of 20 mm; a space that communicates with the flow channel and gradually narrows in a direction perpendicular to the blood flow; and a space that communicates with the space and extends in a direction perpendicular to the blood flow; This is a blood component separator comprising at least two blood component outlet ports installed vertically apart.
本考案の分離対象となる血液は、全血または全
血の特定の分離成分、抗凝結剤等を混じた全血を
主成分とする液体である。 Blood to be separated in the present invention is whole blood or a liquid whose main component is whole blood mixed with a specific separated component of whole blood, an anticoagulant, and the like.
本考案の分離器の容積は50mlより大きく、500
ml以下であることが望ましい。 The volume of the separator of this invention is larger than 50ml, 500ml
It is desirable that it is less than ml.
本考案の流路を流れる血液流の深さは、0.2〜
20mm、好ましくは0.2〜10mmであることが望まし
く、さらに0.5〜５mmであることがより望まし
い。 The depth of the blood flow through the flow path of this invention is 0.2~
The thickness is preferably 20 mm, preferably 0.2 to 10 mm, and more preferably 0.5 to 5 mm.
流路の血液流の線速度は0.5〜200mm／分である
ことが望ましく、１〜100mm／分であればさらに
よく、５〜50mm／分であることが最も好ましい。 The linear velocity of the blood flow in the channel is preferably 0.5 to 200 mm/min, more preferably 1 to 100 mm/min, and most preferably 5 to 50 mm/min.
血液流の深さが20mmを超えると、赤血球の沈降
行程が長くなりすぎ、効率的な成分分離を行なう
ことが困難になる。深さが0.2mmよりも小さくな
ると、実用的な線速度の流れにおいて血漿と血球
との分離がうまく行なわれにくくなる。これは微
小血管内を血液が流れるとき、血球がランダムに
動かず流れの方向に整列したまま押し流され、粘
度が異常に小さくなるフアラーリンビスト効果
（Fahraeus-Lindqvist効果）と同じ現象が起こる
ために、血球の分離が行なわれにくくなるものと
考えられる。 When the depth of blood flow exceeds 20 mm, the sedimentation process of red blood cells becomes too long, making it difficult to perform efficient component separation. When the depth is less than 0.2 mm, it becomes difficult to separate plasma and blood cells properly in a flow at a practical linear velocity. This is because when blood flows through microvessels, the same phenomenon as the Fahraeus - Lindqvist effect occurs, in which blood cells do not move randomly but are pushed away while remaining aligned in the direction of flow, resulting in an abnormally low viscosity. In addition, it is thought that separation of blood cells becomes difficult.
本考案に用いられる、血液を流すための流路と
しては、赤血球の相互作用を大きくし、その凝集
塊形成を促進させるためには、薄い層状、もしく
は、細い管状の流路であることが好ましく、細い
管状の場合には、その断面積が３cm2以下、より好
ましくは0.0003〜１cm2、更に好ましくは0.001〜
0.5cm2の流路が用いられる。 The channel used in the present invention for flowing blood is preferably a thin layer or a thin tubular channel in order to increase the interaction of red blood cells and promote the formation of aggregates. , in the case of a thin tubular shape, its cross-sectional area is 3 cm 2 or less, more preferably 0.0003 to 1 cm 2 , even more preferably 0.001 to 1 cm 2
A 0.5 cm 2 channel is used.
管状の流路の形状は、円柱状、だ円柱状、六角
柱状など形状を問わずに使用できるが、容易にた
ばね接着することが可能な、円柱状、六角柱状の
形状が好ましい。 The shape of the tubular flow path can be any shape such as a cylinder, an elliptical cylinder, a hexagonal cylinder, etc., but a cylinder or a hexagonal cylinder is preferable because it can be easily attached with a spring.
本考案に用いられる複数の流路は、その全容積
が分離血液成分の排出口に連通した空間部とほぼ
同等もしくはそれより大きな容積をもつことが好
ましい。 It is preferable that the total volume of the plurality of channels used in the present invention is approximately equal to or larger than the space communicating with the discharge port for the separated blood components.
血液導入口より導入された血液は、粘度が高い
ため、層状のせまい空間内で拡がることはむづか
しく、あらかじめ血液流路内へ均一に血液を供給
することがぜひとも必要である。そのために血液
導入口に連通した空間部は、血液が血液流路内を
できるだけ均一に流れるように、流れを乱すこと
なく、均一に分配されるように、血液導入口より
なだらかに拡大して血液流路に連通する。また血
液流路の下流側に連通した空間部は、形成された
連銭状の赤血球凝集塊を破壊することなく、分離
した血液成分を再混合しないように、血液流路よ
りなだらかに縮少して、血液成分の導出口へと連
通している。 Since the blood introduced through the blood inlet has a high viscosity, it is difficult for it to spread within the narrow layered space, and it is absolutely necessary to supply the blood uniformly into the blood flow path in advance. Therefore, the space communicating with the blood inlet is expanded gently from the blood inlet so that the blood flows as uniformly as possible within the blood flow path and is evenly distributed without disturbing the flow. Communicates with the flow path. In addition, the space communicating with the downstream side of the blood flow path is narrowed gently from the blood flow path so as not to destroy the formed roule-shaped red blood cell aggregate and to prevent the separated blood components from being remixed. , which communicates with the blood component outlet.
本考案の装置の容積は少なくとも50mlあること
が実用的に望ましい。またこの装置が体外循環を
行なう目的で使用される時は、500ml以下である
ことが望ましい。 It is practically desirable that the volume of the device of the present invention is at least 50 ml. Furthermore, when this device is used for the purpose of extracorporeal circulation, it is desirable that the volume be 500 ml or less.
本考案の装置を好適に使用するためには、血液
を本装置の分離血液成分の導出口を有する空間部
における血液の滞留時間が、２分以上になるよう
に流すことが望ましい。しかし、血液の滞留時間
が余り長すぎると、流せる血液量が少なくなり、
得られる分離成分の量が低下するので好ましくな
い。 In order to suitably use the device of the present invention, it is desirable to flow blood so that the residence time of the blood in the space of the device having the outlet for the separated blood components is 2 minutes or more. However, if the retention time of blood is too long, the amount of blood that can flow decreases.
This is not preferred because the amount of separated components obtained is reduced.
血液流は35〜42℃、より好ましくは37〜40℃に
加温されることが望ましい。赤血球の凝集は温度
が高いほど加速されるが、余り高いと赤血球の溶
血などが起こり好ましくない。 Desirably, the blood flow is heated to 35-42°C, more preferably 37-40°C. Aggregation of red blood cells is accelerated as the temperature increases, but if the temperature is too high, hemolysis of red blood cells may occur, which is undesirable.
本考案の装置の材質は、内圧によつて変形しな
い硬質のものであることが必要である。また有毒
な溶出物がなく、血栓形式を起こしにくい材質で
あることが必要である。これらの点から、ポリカ
ーボネート樹脂、ポリプロピレン樹脂、ポリエチ
レン樹脂、ポリ塩化ビニール樹脂、アクリル樹脂
などの合成樹脂や、アルミニウム、ステンレスス
チールなどの金属等を用いることができる。本考
案の装置の外側をシリコーン樹脂などの軟質材料
で作製し、その周囲を剛質材料、たとえばアルミ
ニウムなどの金属製のシエルにて補強して用いる
ことも可能である。金属製のシエルを用いた場合
には、その内部にヒーターを埋設することによ
り、血液の加熱を容易に行なうことも可能であ
る。 The material of the device of the present invention must be hard and not deformed by internal pressure. It is also necessary that the material be free of toxic eluates and unlikely to cause thrombosis. From these points, synthetic resins such as polycarbonate resin, polypropylene resin, polyethylene resin, polyvinyl chloride resin, and acrylic resin, metals such as aluminum and stainless steel, etc. can be used. It is also possible to make the outside of the device of the present invention from a soft material such as silicone resin, and to reinforce the periphery with a rigid material, for example a shell made of metal such as aluminum. When a metal shell is used, blood can be easily heated by embedding a heater inside the shell.
本考案における血液を流すための流路として
は、実質的に水平な方向もしくは流れ方向に対し
て上昇角度を与えるように、血液の流路を設ける
ことが望ましい。流路は平滑であることが望まし
いが、ある程度の粗面であつてもさしつかえな
い。 In the present invention, the blood flow path is preferably provided in a substantially horizontal direction or at an upward angle with respect to the flow direction. Although it is desirable that the channel be smooth, it is acceptable even if the channel is rough to some extent.
以下、図面によつて本考案を説明する。 The present invention will be explained below with reference to the drawings.
第１図は本考案の血液成分分離器の一例を示す
上からみた外観図である。 FIG. 1 is an external view from above showing an example of the blood component separator of the present invention.
第２図は本考案の分離器の一例を示す斜視図で
あつて、内部が判り易いように、正面を断面図で
示し、血液の分離している挙動を示してある。第
２図において、容器１は血液導入口２に連通する
空間部Ａ３、該空間部Ａと連通した流路４、流路
４と連通した空間部Ｂ８、該空間部Ｂと連通した
導出口６，７とを有する。血液は抗凝固剤を加え
られて導入口２より、空間部Ａ３中に導入された
のち、流路４に連続的に送りこまれる。流路４を
出た血液は空間部Ｂ８にて、多血小板血漿である
上澄層と赤血球等からなる沈殿層とに分離され
る。分離されたそれぞれの成分は導出口６，７よ
り継続的に排出される。 FIG. 2 is a perspective view showing an example of the separator of the present invention, and in order to make the interior easier to understand, the front is shown in a sectional view to show the behavior of blood separation. In FIG. 2, the container 1 includes a space A3 communicating with the blood inlet 2, a channel 4 communicating with the space A, a space B8 communicating with the channel 4, and an outlet 6 communicating with the space B. , 7. The blood is introduced into the space A3 through the inlet 2 with an anticoagulant added thereto, and is then continuously fed into the flow path 4. The blood exiting the flow path 4 is separated into a supernatant layer consisting of platelet-rich plasma and a precipitate layer consisting of red blood cells and the like in the space B8. The separated components are continuously discharged from the outlets 6 and 7.
排出される上澄層への沈殿層の成分の混入を抑
制するためには、光学的方法などによる検知手段
を使用することにより、各成分の排出速度を調節
することが望ましい。 In order to suppress the mixing of components of the sediment layer into the discharged supernatant layer, it is desirable to adjust the discharge rate of each component by using a detection means such as an optical method.
第３図は、本考案の流路形成板によつて作られ
た複数の流路を有する分離器の一例を示す斜視図
であつて、このような形状の分離器も第２図の分
離器と同様に使用できる。 FIG. 3 is a perspective view showing an example of a separator having a plurality of flow paths formed by the flow path forming plate of the present invention, and a separator having such a shape is also similar to the separator shown in FIG. It can be used in the same way.
以上の如く本考案の分離器は、遠心力場を使用
することなく、きわめて効率よく、血液成分の分
離を行なうことができるのみならず。せまい病室
等でも容易に施行できるために、慢性関節リウマ
チなど血沈が坑進した膠原病患者の血漿交換や血
漿浄化治療などにもきわめて有用である。 As described above, the separator of the present invention not only can separate blood components extremely efficiently without using a centrifugal force field. Because it can be performed easily even in small hospital rooms, it is extremely useful for plasma exchange and plasma purification treatments for patients with collagen diseases such as rheumatoid arthritis, where blood sedimentation has progressed.
第１図は本考案の実施例である分離器を上から
みた平面図である。第２図は上記実施例の斜視図
であり、内部が判りやすいように正面を断面図に
て示し、血液が分離していく挙動を示してある。
第３図は本考案の分離器の他の一例を示す斜視図
である。
１……容器、２……血液導入口、３……空間部
Ａ、４……血液流路、５……流路形成板、６……
上部導出口、７……下部導出口、８……空間部
Ｂ。
FIG. 1 is a top plan view of a separator according to an embodiment of the present invention. FIG. 2 is a perspective view of the above-mentioned embodiment, and the front is shown in a sectional view so that the inside can be easily understood, and the behavior of blood separation is shown.
FIG. 3 is a perspective view showing another example of the separator of the present invention. DESCRIPTION OF SYMBOLS 1... Container, 2... Blood inlet, 3... Space A, 4... Blood channel, 5... Channel forming plate, 6...
Upper outlet, 7... lower outlet, 8... space B.
Claims (1)
に対してなだらかに拡大した空間部と、該空間部
に連通した、その垂直方向の厚さが0.2〜20mmで
ある少なくとも一つの血液流路と、該流路に連通
し、血液の流れと直角方向に対してなだらかに縮
少した空間部と、該空間部に連通し、血液の流れ
と垂直方向に上下離れて設置された少なくとも２
個の血液成分の導出口とからなる血液成分分離
器。 A space that communicates with the blood inlet and expands gently in a direction perpendicular to the blood flow, and at least one blood flow path that communicates with the space and has a thickness in the vertical direction of 0.2 to 20 mm. a space portion that communicates with the flow path and is gently contracted in a direction perpendicular to the blood flow; and at least two space portions that communicate with the space portion and are vertically spaced apart from each other in a direction perpendicular to the blood flow.
A blood component separator comprising two blood component outlet ports.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1981174597U JPS5880241U (en) | 1981-11-26 | 1981-11-26 | blood component separator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1981174597U JPS5880241U (en) | 1981-11-26 | 1981-11-26 | blood component separator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5880241U JPS5880241U (en) | 1983-05-31 |
| JPS62688Y2 true JPS62688Y2 (en) | 1987-01-09 |
Family
ID=29966630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1981174597U Granted JPS5880241U (en) | 1981-11-26 | 1981-11-26 | blood component separator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5880241U (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1765228A4 (en) * | 2004-06-28 | 2009-06-10 | Haemonetics Corp | Blood component separation system with stationary separation chamber |
| JP2013170990A (en) * | 2012-02-22 | 2013-09-02 | Ritsumeikan | Separation collection chip and separation collection method |
-
1981
- 1981-11-26 JP JP1981174597U patent/JPS5880241U/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5880241U (en) | 1983-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4409106A (en) | Apparatus and method for separating blood components | |
| EP0057907B1 (en) | Apparatus for separating blood components | |
| JPS622820B2 (en) | ||
| JP4304264B2 (en) | Particle separation method and apparatus | |
| US4424132A (en) | Apparatus and method for separating blood components | |
| US8226537B2 (en) | Blood processing apparatus with cell separation chamber with baffles | |
| JP2001500053A (en) | Multi-element filter | |
| US10704023B2 (en) | Separating composite liquids | |
| US4765899A (en) | Apparatus for continuous separation of leukocyte/platelet-enriched fraction from whole blood | |
| US4663058A (en) | Process for continuous separation of leukocyte/platelet-enriched fraction from whole blood | |
| JPH11503664A (en) | Intermittent collection of mononuclear cells | |
| US10047342B2 (en) | Elutriation chamber for an elutriator system | |
| JPS648562B2 (en) | ||
| CN101534917A (en) | Systems and methods of microfluidic membraneless exchange using filtration of extraction fluid outlet streams | |
| WO2007106666A2 (en) | System, chamber, and method for fractionation, elutriation, and decontamination of fluids containing cellular components | |
| JPH11503665A (en) | Overflow collection of scattered components such as mononuclear cells | |
| JPS5890513A (en) | Method and apparatus for fractional collection of blood component | |
| JPS62688Y2 (en) | ||
| US20060086675A1 (en) | System, chamber, and method for fractionation and elutriation of fluids containing particulate components | |
| US6423023B1 (en) | Method and apparatus for enhanced plasmapheresis | |
| Fourtounas | Cell saver physics–a review | |
| JPS6230782B2 (en) | ||
| JPS6230781B2 (en) | ||
| JPS5841822A (en) | Separating method of blood component and apparatus therefor | |
| JPS6219177A (en) | Blood treating apparatus |